ClinicalTrials.gg
Not yet recruitingNCT06871501GIM29-GIMOMICUpdated Mar 13, 2025

"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

An observational study in Breast Cancer, sponsored by Consorzio Oncotech. Not yet recruiting at 25 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Consorzio Oncotech · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Breast Neoplasms by Consorzio Oncotech — 3 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Consorzio Oncotech.

Started
2025
the only one that year
Observational
5 of 16
3 open now
Registered
16th of 16
by date

Among the 16 studies in Breast Neoplasms by Consorzio Oncotech, this one is the only one that started in 2025, is one of 5 observational ones, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 16 studies in Breast Neoplasms by Consorzio Oncotech are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Breast Neoplasms by Consorzio Oncotech, or all of them as a file.
02

Study summary

The study aims to establish an Italian registry for the implementation of the use of genomic tests in patients with HR +/HER2- breast cancer at intermediate risk of recurrence after the entry into force of the Ministerial Decree of 18/05/2021. The decree has established the reimbursability of genomic testing for breast cancer patients, thereby influencing clinical decision-making and patient management within Breast Units. In addition, the study aims to evaluate the clinical impact of the use of genomic testing on the type of adjuvant treatment, in terms of change of treatment indication by breast units according to the test result.

Read the detailed description

The study is a retrospective and prospective, non-interventional, observational registry-based study that will enroll all patients with ER +/HER2-negative, T1-3 breast cancer with negative axillary lymph nodes or up to 3 positive axillary lymph nodes for whom Breast Units require genomic test to support adjuvant therapy decisions, according to current clinical practice. For prospective cohort: genomic tests will be performed on all patients who meet the criteria for access to testing as set out in the Ministerial Decree of 18/05/2021, unless otherwise agreed by the reference Breast Unit, in accordance with the specific diagnostic pathways activated by each site. For retrospective cohort: data for patient referred for genomic testing following Ministerial Decree 18/05/2021 will be collected. The patient's baseline demographic characteristics, tumor clinicopathological features, pre and post-test therapeutic indication (CET vs ET), the test results, the actual adjuvant treatment received and time around data will be recorded in a dedicated registry.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Genomic testing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study is a retrospective and prospective, non-interventional, observational registry-based study that will enroll all patients with ER +/HER2-negative, T1-3 breast cancer with negative axillary lymph nodes or up to 3 positive axillary lymph nodes for whom Breast Units require genomic test to support adjuvant therapy decisions, according to current clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. . Age ≥ 18 years
  2. PS 0-1
  3. confirmed early breast carcinoma with positivity for hormone receptors (ER+ IHC >10%) and negative (IHC value 0 1+ and/or FISH not-amplified)
  4. Primary resective surgery for early breast cancer with adequate assessment of lymph node status (sentinel lymph node or complete axillary dissection), with one of the following diagnostic stages:

    • T1-3, N0, M0
    • T1-3, pN1mic, M0
    • T1-3, pN1a, M0
  5. Indication for treatment with endocrine therapy (ET) or chemo endocrine therapy (CET), according to the decision of the reference Breast Unit
  6. Meeting the criteria for "intermediate" risk, i.e., no "low" or "high" risk of recurrence, as defined in the ministerial decree of 18/05/21:

    • Low risk defined by at least 5 of the following: G1, T1a-b, KI67 \< 15, N neg, ER > 80%
    • High risk, defined by at least 4 of the following: G3, T > 2, Ki67 > 30, N pos, ER \< 30%
  7. Indication for genomic test (Oncotype DX®, Mammaprint®, PAM50 Prosigna®, Breast Cancer Index®, EndoPredict®) by the Breast Unit
  8. Ability to provide written to participate in the registry study, approved by the local Ethics Committee.
  9. The patient underwent genomic testing starting from September 2021

Exclusion criteria

Exclusion Criteria:

  1. Low-risk and High-risk patients as defined in the Ministerial Decree of 18/05/21
  2. ER negative and/or positive tumours
  3. More than 3 lymph nodes involved at clinical/pathological staging
  4. Invasive tumours \<2mm evaluated by local pathologists
  5. Previous history of breast cancer
  6. Synchronous breast cancers
  7. Multifocal tumours
  8. disease
  9. to treatments
  10. Performance status (PS ) > 1 and / or other clinical factors that would make the patient a candidate and unsuitable for systemic adjuvant treatment or have received an exclusive indication for precautionary hormone therapy as part of the Breast Unit collegial assessment.
  11. Psychiatric diagnosis that may affect the ability to participate in this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective cohort

    For prospective cohort: genomic tests will be performed on all patients who meet the criteria for access to testing as set out in the Ministerial Decree of 18/05/2021, unless otherwise agreed by the reference Breast Unit, in accordance with the specific diagnostic pathways activated by each site.

  • Retrospective cohort

    For retrospective cohort: data for patient referred for genomic testing following Ministerial Decree 18/05/2021 will be collected. The retrospective cohort will contribute to expanding our knowledge of the clinico-pathological characteristics of patients who underwent genomic testing. This comprehensive understanding of the clinico-pathological profile of patients undergoing genomic testing will enable a more thorough assessment of the clinical dynamics and therapeutic decisions associated with genomic testing results, including the analysis of their possible evolution over the years.

06

What researchers measure

Primary outcomes

  1. Establishment of a prospective Italian observational registry for the implementation of genomic tests in patients with HR +/HER2- breast cancer

    Establishment of a prospective Italian observational registry for the implementation of genomic tests in patients with HR +/HER2- breast cancer at intermediate risk of recurrence after the adoption of the Ministerial Decree of 18/05/2021

    Time frame: Until November 2026

  2. Measurement of the impact of genomic testing on adjuvant treatment choice (CET vs ET only)

    Rate of adjuvant treatment choice's change following the genomic test result (Breast Unit's pre-test vs post-test indication)

    Time frame: Until November 2026

  3. Measurement of the impact of genomic testing on adjuvant treatment choice (CET vs ET only)

    Saving in adjuvant chemotherapy compared to the pre-test indication

    Time frame: Until November 2026

  4. Measurement of the impact of genomic testing on adjuvant treatment choice (CET vs ET only)

    Addition of adjuvant chemotherapy to endocrine therapy alone compared to the pre-test indication

    Time frame: Until November 2026

  5. Measurement of the impact of genomic testing on adjuvant treatment choice (CET vs ET only)

    Type of adjuvant treatment the patient actually received

    Time frame: Until November 2026

Secondary outcomes

  1. Record the predominant demographic and clinical characteristics of the patients for whom genomic testing was indicated.

    Record the predominant demographic and clinical characteristics of the patients for whom genomic testing was indicated.

    Time frame: Until November 2026

  2. Describe which genomic tests are used and the factors involved in the selection of genomic tests.

    Describe which genomic tests are used and the factors involved in the selection of genomic tests.

    Time frame: Until November 2026

  3. Identify any inequalities in access to the genomic tests in different geographical areas of the country.

    Identify any inequalities in access to the genomic tests in different geographical areas of the country.

    Time frame: Until November 2026

  4. Analyse the prescriptive adequacy and the compliance

    With the inclusion criteria for genomic tests.

    Time frame: Until November 2026

  5. Record the distribution of demographic and clinical characteristics in the group of patients with changed treatment recommendation compared to the group of patients with unchanged indication after genomic test.

    patient age comorbidities, tumour size, number of positive lymph nodes, tumour grade

    Time frame: Until November 2026

  6. Evaluate the impact of the test on the timing of activation of adjuvant treatment

    Time from diagnosis to request for genomic test

    Time frame: Until November 2026

  7. Evaluate the impact of the test on the timing of activation of adjuvant treatment

    Time from request for the genomic test to result

    Time frame: Until November 2026

  8. Evaluate the impact of the test on the timing of activation of adjuvant treatment

    Time from test result to activation of adjuvant chemotherapy, if indicated

    Time frame: Until November 2026

  9. Evaluate the impact of the test on the timing of activation of adjuvant treatment

    Time from diagnosis to activation of adjuvant chemotherapy, if indicated

    Time frame: Until November 2026

07

Study locations

25 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for May 2025, 2 months later.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 2 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 12, 2025
StartEst.
Mar 2025
Primary completionEst.
May 2025
CompletionEst.
Nov 2026
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06871501
Lead sponsor
Consorzio Oncotech
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
Mar 2025 (estimated)
Primary completion
May 2025 (estimated)
Completion
Nov 2026 (estimated)
Last update
Mar 13, 2025

Study contacts

Mario G Mario Giuliano, MD
Contact
m.giuliano@unina.it
0817463762 ext. 3762
GIM29-GIMOMIC S GIM29-GIMOMIC Service
Contact
helpdesk.gim29@oncotech.org
+39 089301545 ext. 1545

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion